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Abstract
Laron syndrome is a congenital autosomal recessive disorder that is caused by a mutation in the growth hormone
receptor. People with this syndrome have an insensitivity to growth hormone. Insulin-like growth factor 1 is produced
by the liver in response to GH stimulus. It is responsible for systemic GH activities. If there is something wrong with the
growth hormone receptor there will be decreased levels of IGF-1. Low IGF-1 levels cause physical deformities notable
short stature. Additionally, people with low levels of IGF-1 have a natural resistance to cancer. This article discusses the
ways that the decreased levels of IGF-1 in Laron subjects protect the body from cancer.
Introduction
Laron Syndrome, eponymously named after the scientist Zvi
Laron who first discovered the syndrome, is a growth hormone
insensitivity syndrome. People with Laron Syndrome have a genetic mutation in the growth hormone receptor. These patients
have a normal level of growth hormone but a reduced level of
Insulin-like Growth Factor 1 (IGF-1) and are characterized by
dwarfism and other physical deformities. Remarkably, patients
with this condition have been proven to be immune to cancer.
Through research on Laron Syndrome scientist have found a
link between a key growth hormone and resistance to cancer.

Methods and Materials
Information was compiled from various articles that were obtained through Touro College’s library database and Pubmed.
The information was narrowed down to those directly related
to the topic. The information extracted and synthesized was
used to hypothesize why Laron Syndrome patients are immune
to cancer.

Background information
Data shows that Laron Syndrome (LS) patients have normal levels of, and a normal, GH molecule, but a defect in the Growth
Hormone Receptor gene (GHR). Patients with LS have either a
gene deletion or a point mutation in this gene (Wood & Savage,
1996).

this syndrome. One hundred and forty eight are known to have
Semitic origin. One third of the people with this syndrome live
in Loja, Ecuador which is where most of the genetic studies take
place. The people in Loja, Ecuador are said to have ancestors
who converted to Christianity during the Spanish Inquisition
(Wood & Savage, 1996).
Laron syndrome is a congenital autosomal recessive disorder.The
parents of an individual with Laron syndrome must each have a
copy of the mutated gene while displaying no signs of the syndrome. People with Laron Syndrome have postnatal growth failure; it begins with “subnormal birth length, retarded brain growth,
acromicria, also of the facial bone, defective and crowded teeth,
sparse hair, small gonads and genitalia, obesity, retarded skeletal
maturation, delayed puberty, hypoglycemia. As these patients get
older they have obesity, muscle underdevelopment and weakness, osteoporosis, hypercholesterolemia, hyperinsulinemia, and
various degrees of glucose intolerance (Yamamoto et al, 2007).”
There is wide phenotypic variability among patients with this
syndrome. With that said, there is uncanny similarity between
patients with LS even with variability in genotype and even if they
are from different places. In the image below of two men with

Mutations in the growth hormone receptor interrupts the JAKSTAT signaling pathway which stimulates the production of
IGF-1. The JAK-STAT signaling pathway brings information from
chemical signals outside the cell, through the cell membrane,
and into the cell where gene promoters on the DNA in the cell
nucleus can causes DNA transcription and activity in the cell.
The mutation in the Growth Hormone Receptor, leads to an
inability of the extracellular domain to bind growth hormone
and stimulate the production of IGF-1 (Gastier et al., 2000).
Cited from Rosenbloom and Guevara-Aguirre that in 1966,
Laron, Pertzelan and Mannheimer did research on the high
levels of growth hormones in patients with clinical and laboratory signs of growth hormone deficiency (Rosenbloom and
Guevare-Aguirre, 1998). There are ~251 reported people with
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Laron Syndrome, it is evident that there is a similarity in physical
features.

deficiency is the main determinant of a reduced birth size.
(Puche & Castille-Cortazar, 2012).

The man in figure A and C is 21 years old with a height of 126.6
cm. The man in B and D is 28 years old and has a height of 115
cm. Analysis of the faces indicate different craniofacial phenotype, but still both men with Laron Syndrome have an uncanny
resemblance (Rosenbloom and Guevare-Aguirre, 1998).

Research done on the effects of GH to stimulate skeletal
growth has proven that GH directly stimulates bone growth.
Additionally, GH stimulates the production of IGF-1 which
will then promote bone growth. This proves, along with
other findings, that IGF-1 and GH work independently and
synergistically to promote postnatal body growth (Puche &
Castille-Cortazar, 2012).

Patients with LS have extremely low levels of insulin-like growth
factors, below the 0.1st percentile for age, such as IGF-I which
is the major hormone responsible for growth and it is under the
control of GH. Patients with GHD also have a low level of IGF-I
but those patients responded well to exogenously administered
GH, whereas patients with LS did not which is a characteristic
of LS. This is the primary difference between GHD and GHRD.
LS patients also have extremely low levels of Insulin-like growth
factor binding proteins (IGFBPs). Specifically, IGFBP-3 levels are
decreased in LS patients (Wood & Savage, 1996).

Insulin-like growth factor 1 (IGF-1)
IGF-1 is a 70 amino acid polypeptide hormone involved in endocrine, paracrine, and autocrine functions. An original name for
this hormone was somatomedin C because it was under the
control and mediates the effect of the growth hormone. The
name was changed to Insulin-like because it shared a similarity
to proinsulin. Also, it mimics insulin activity such as stimulating
glucose uptake in the cells. Additionally, IGF-1 has mitogenic capabilities (Puche & Castille-Cortazar, 2012).

Synthesis and Circulation
Growth hormone is secreted by the pituitary gland and it stimulates the production of IGF-1 by acting on the liver where
it is made. The pituitary gland releases GH and it works
together with the liver in a negative feedback mechanism to
stimulate the secretion of IGF-1; increased levels of IGF-1
cause a decrease in production of GH which stimulates the
production of less IGF-1 (Puche & Castille-Cortazar, 2012).
Recent research by Puche and Castille-Cortazar is uncovering IGF-1 as an independent and self-sufficient peptide,
separate from GH. IGF-1 is produced mainly by the liver
in response to the endocrine GH stimulus, but it is also
secreted by multiple tissues for autocrine and paracrine
purposes. In tissues throughout the body it is evident that
IGF-1 expression is regulated and stimulated by other factors besides GH, such as estrogen in the uterus (Puche &
Castille-Cortazar, 2012).
The stimulatory role of IGF-1 on intrauterine growth is
GH-independent. Regardless of the levels of GH, IGF-1
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Central nervous system development
IGF-1 binds to IGF-1R a cell surface receptor. When IGF-1
binds to the receptor intracellular signaling is initiated. The
AKT signaling pathway, which is a stimulator of cell growth
and proliferation, and a potent inhibitor of programmed cell
death, is activated.
IGF-1 production coincides with periods of neuron progenitor
proliferation and differentiation. The role of IGF-1 in the brain
is not only neuronal produced IGF-1. Systemic IGFs (mainly
produced by the liver) can cross the blood-brain-barrier and
are also involved in these processes. Labeled IGFs were placed
in the carotid arteries of rats and were later on detected in
the choroid plexus, median eminence, brain arterioles, and
parenchyma. This coincides with the data that confirmed the
presence of IGF-1 receptors in the brain capillary endothelial
cells which constitutes the BBB, and the role in internalizing
IGFs from circulation to the CNS. There is evidence that
growth factors, GH, basic fibroblast growth factor; nutrition;
and injury influence and regulate IGF-1 expression in the brain.
All of the growth abnormalities that are attributed to LS patients (see above), indicate that IGF-1 plays a critical role on
brain development and function.

Current therapeutic options and limitations
In 1980, Recombinant Human IGF-1 (rhIGF-1), Mecasermin
became available for experimental therapy for people with severe primary IGF-1 deficiency. An average of 8.5 cm in height
was grown the first year. Besides for an increase in height, patients with rhIGF-1 treatment had an increase in testosterone
levels, testicular size and stretched penile length. This shows
the effect of IGF-1 on sex hormones and organs in male patients (Puche & Castile-Cortazar, 2012).
Another treatment that the FDA approved was a combination
of IGF-1 and IGFBP-3, Mecasermin Rinfabate. This was thought
to have been a smarter alternative to Recombinant human
insulin growth factor 1 (rhigf-1) because it was supposed to
extend the duration of IGF-1 in the body. Interestingly enough,
when the combination of IGF-1 and IGFBP-3 were used to
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treat patients compared to a control group who only were
treated with IGF-1, those treated with IGF-1 alone had better
results (Puche & Castile-Cortazar, 2012).

Prevalence of malignancy in the surveyed subjects

Dosing guidelines for rhIGF-1 are still being debated. The international Congress of Endocrinology has stated that both
one and two injections of rhIGF-1 is safe and efficient. One
or two injections regimen have the same growth velocity. By
carefully monitoring the IGF-1 serum levels the negative side effects can be avoided. Long-term rhIGF-1 has reported negative
side effects. These side-effects, namely tachycardia were easily
managed without treatment discontinuation (Puche & CastileCortazar, 2012).
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A novel and efficient method for hormone replacement therapy
is being developed using Sertoli cells. Sertoli cells are originally from the male testis, and they can ameliorate development
and survival and function of different cell types. In the “Laron
mouse” it was successfully reported that pre-pubertal sertoli
cells in microcapsules can successfully promote growth. There
was a significant increase in body weight and body length compared with the control “Laron mouse” treated with empty capsules. IGF-1 serum levels were noticeably increased in mice
treated with Sertoli cells microcapsules. The reduction in side
effects, the increase in growth, and the fact that sertoli cells
do not require intramuscular daily injections are all reasons
that sertoli cell treatment is preferred over rhigf-1 treatment
(Kinam Park, 2012).
Puche and Castille-Cortazar cite a study done by Steuerman R,
Shevah O, Laron Z. on the prevalence of cancer in people with
Laron Syndrome compared to their family members. This study
proved that IGF-1 deficiency provides protection against cancer.
Interestingly, this study reported that Laron Syndrome patients
are protected against future cancer development, even when
treated with rhIGF-1. (Puche & Castile-Cortazar, 2012).
The positive results of exogenously administered IGF-1 in subjects without IGF-1 deficiency, to use its anti-inflammatory,
hematopoietic, antioxidant, metabolic or anabolic properties, is
not clearly determined (Puche & Castile-Cortazar, 2012).

Discussion
Studies have shown that patients with overexpression of IGF-I
are more susceptible to tumors. Laron set out to determine
if patients with IGF-I deficiency (LS) are less likely to develop
cancer. Two hundred and twenty eight patients with IGF-1 deficiency and 338 of first and second degree family members were
surveyed. Cancer was not a cause of death in GHRD patients of
any age.Ten to twenty four percent of the family members had a
history of malignancies. Only one GHRD subject monitored had
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(Laron & Shevah, 2006)
cancer, papillary serous epithelial tumor in the ovary. The table
below shows the prevalence of the malignancies in patients and
family members. Because of the results of this and further studies, IGF-I receptor blockers are being developed as drugs for
cancer therapy (Shevah & Laron, 2006)

What is the link between GH and cancer?
Data suggest that the GH/IGF-1 axis shows an important role
in cancer.
Growth Hormone does not have the ability to induce cancer,
but it has cancer-enhancing properties. There are many different factors that influence the different effects of the IGF-1. The
powerful effects of IGF-1 on the stages of cancer development
and behavior include “cellular proliferation and apoptosis, angiogenesis and metastasis…” Additionally, IGF-1 is a powerful
antiapoptotic agent. These opposing effects relate strongly to
cancer. Firstly, there is increased proliferation causing epithelial cell turnover within tissues. Secondly, there is an imbalance
in the control between proliferation and cell death because of
the anti-apoptotic effects which leads to hyperproliferation.
This is the first stage of development of many cancers. Thirdly,
this imbalance between cell proliferation and cell death causes
the favoring of cell survival even in damaged cells. This could
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accelerate carcinogenesis. Both the second and third point are
ways that cancer is accelerated not initiated (Puche & CastileCortazar, 2012).
Research in epidemiological studies have shown a correlation
between the role of GH and carcinogenesis. People with more
growth hormone are naturally taller. The Boyd-Orr study
showed an SD of 1 inch height to be linked with a 42% higher
risk of cancer later in life in boys. High birth weight, high stature
at 14, low body mass index, and peak growth at early age were
independent risk factors for breast cancer. (Jenkins et. al., 2005)
Epidemiological date found a correlation between adult height
and cancer. An increase in breast cancer by 22 % was noted with
increased height. These studies suggest that the GH/IGF-1 axis
plays an important role in cancer development and behavior
(Jenkins et. al., 2005). Many pharmaceutical companies are creating drugs that inhibit the IGF-1 signaling to inhibit breast cancer
proliferation and block the mitogenic effects of exogenous IGF1.They are also experimenting with Inhibitors of the IGF-IR as a
chemotherapeutic (Jenkins et. al., 2005).
Studies on mice were done to provide evidence to this relationship. Transgenic mice with human GH and agonist for the
IGF-1 receptor have increased incidence of breast tumor development. On the other hand, mice with a non-functioning GH
receptor (serum GH/IGH-1 levels of ten percent the normal),
showed inhibition of growth of transplanted breast cancer cells.
Even the serum was less mitogenic to breast cancer cells in
vitro than a control serum, this changed once IGF-1 was added
to the serum. Recent studies have shown that mice transfected
with growth hormone receptor antagonists have less incidences
of carcinogenesis (Guevara-Aguirre et. al., 2011).
Another study done on mice was used to prove the influential effects IGF-1 exerts on the metastatic power of cancers
(Guevara-Aguirre et. al., 2011). This is an extremely important
aspect of cancer as the metastatic spread of cancer is usually
what causes mortality. A cell from the LCC6 metastatic breast
cancer cell line was transfected with a truncated IGF-1 receptor
that silenced the expression of IGF-1 receptor and inhibited
IGF-1 signaling. These cells were transplanted into mice and the
metastatic spread was measured. Mice that were transplanted
with wild type cells had multiple pulmonary metastases, but the
mice transplanted with the transfected cells were completely
absent of any metastases (Guevara-Aguirre et. al., 2011).
Another reason how the GH/IGF-1 axis can cause cancer is
by promoting an increased DNA damage. Experiments on
Saccharomyces cerevisiae yeast indicate that mammalian growth
signaling pathway genes promote an increase in DNA mutations by elevating superoxide production and increasing DNA

122

damage. This is particularly important because it hypothesizes
that, in addition to the possibility that the GH/IGF-1 axis may
promote cancer by preventing apoptosis of the damaged cells,
it can increase DNA damage in cells that can ultimately lead
to cancer. To test this hypothesis, human mammary epithelial
cells (HMECs) were placed in a medium that contained 15%
serum from either Laron syndrome subjects or their relatives.
The cells were then treated with H2O2 followed by comet analysis to detect DNA strand breaks. The comet analysis indicated
that cells incubated in serum from GHRD patients had fewer
DNA breaks after treatment in comparison to cells incubated in
serum from relatives. This teaches that serum from GHRD subjects can protect against oxidative DNA damage independently
of cell division. It was determined that that IGF-1 signaling was
responsible for the sensitization of cells to oxidative damage via
analysis of DNA damage in MEF cells lacking the IGF-R or overexpressing the human IGF-1R cell (R+ cells). R+ cells had more
DNA damage than did R-cells. (Guevara-Aguirre et. al., 2011).
A study done by Wang and colleagues on rats explains that
down-regulation of GH signaling could block carcinogenesis in
rats. Human prostate cancer cell lines express GH receptors
at levels greater than normal. A rat that does not have GH
because of a mutation was crossed with the Probasin/Tag rat,
a rat which develops prostate carcinomas at 100% incidence
rate. The rats that were homozygous for the GH deficiency had
prostrate tumor incidence and tumor latency reduced relative
to wild type rats. At 25 weeks of age, the rats with no GHR
resulted in a 20% and 80% decrease of carcinoma in the dorsal
and lateral lobes, respectively. At 52 weeks of age, invasive prostate adenocarcinomas were observed in all Probasin/ Tag rats
positive for the Growth Hormone. Conversely, majority of the
Tag rats with the mutation that makes them GH deficient did
not develop invasive tumors (Wang et. al. 2008).
The potent antiapoptotic and mitogenic properties of IGF-1
is linked to an increased risk in developing cancer. It is documented that IGF-1 can promote carcinogenesis at the cellular

(Svensson et. al., 2012)
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level, but evidence is accumulating that circulating IGF-1 can
also promote carcinogenesis. For example, reduction of IGF-1
by dietary restriction slows tumor progression and increase
apoptosis in tumor cells of animal models. And when these
models were treated with recombinant IGF-1 the effects were
reversed. Additionally, IGF-1 gene deletion in mice is linked to
a 75% decrease in circulating IGF-1 levels. Tumor growth and
development was much higher in the control group than transgenic mice.

Biological interactions among insulin, IGF-1 and
IGFPBS
As stated above there are many clinical studies that suggest that
high serum IGF-1 levels associate with increased risk of cancer.
Increasing clinical evidence suggests that low IGF-1 levels are associated with cancer mortality in older men. In numerous studies, the association between circulating IGF-1 levels and cancer
mortality was U-shaped with increased levels of mortality at
both the low and high serum IGF-1 levels.
Serum IGF-1 was extracted from the blood of a large cohort of
elderly men from Sweden. The measurements of serum IGF-1
levels were obtained.The reason for mortality was documented
on the death certificate of the subjects and then used in the
study. Cox proportional hazards was used to analyze the association between serum IGF-1 levels and mortality by cancer. Cox
regression analysis showed that both low and high serum IGF-1
concentration was associated with increased cancer mortality.
The patients with a history of cancer were excluding from the
analysis (Svensson et al, 2012).

IGF-1R Inhibitors as an Anti-Cancer
Because of the role that IGF signaling plays in the promotion
of cell growth and inhibition of apoptosis, IGF blocking is being
developed as a therapeutic potential to protect against cancer.
Currently there are many clinical studies targeting and inhibiting the IGF pathway to promote anti-tumor activities. There
are three main classes of IGF/IGF-1R inhibitor antibodies being
studied in clinical trials; each class inhibits IGF-1R signaling
but through different mechanisms. There has been some small
success in treating patients with select tumor types, but many
trials have been unsuccessful. Researchers are trying to identify
patient selection markers to attain future success in IGF-1R inhibitor development (Chen & Sharon, 2013).
IGF blocking is also being used to overcome chemotherapy
sensitivity. Resistance to chemotherapy is common nowadays.
IGF is implicated in chemotherapy resistance because it promotes proliferation and inhibits apoptosis. Researchers have
tested this hypothesis and have found that IGF-1R inhibitors
have caused significant tumor growth inhibition. Currently,

researchers are testing the combined effect of IGF-1R inhibitors
with a chemotherapeutic (Weroha & Haluska, 2008).

Conclusion
Laron Syndrome subjects participate in groundbreaking genetic
studies to explore the relationship between the deficiency in
the growth hormone receptor and immunity to cancer. This
syndrome is providing insight to, and revolutionizing, the way
cancer is treated and prevented. Because Laron Syndrome subjects have decreased levels of IGF-1 they are protected against
numerous and potentially harmful effects of IGF-1 including cellular proliferation, apoptosis, angiogenesis, and metastasis. The
increased proliferation and decreased apoptosis causes survival
of damaged cells that then spread easily throughout the body,
which could lead to the development of cancer. Because Laron
Syndrome subjects have decreased levels of IGF-1 they are
immune to cancer. The implications of IGF/IGF-1R in cancer
development, maintenance, and progression, is what led to replicating the IGF-1 levels of LS patients to use as an anti-cancer
target. IGF-1 has been successfully inhibited in animal models to
prevent cancer cell growth. Now researchers are beginning to
use IGF-1 reducing agents and blockers as a chemotherapeutic
to prevent cancer.

Abbreviations
IGF-1
LS
GH
GHR
GHD
GHRD
CNS
rhIGF-1
IGFBP
HMEC

Insulin Growth Factor 1
Laron Syndrome
Growth Hormone
Growth Hormone Receptor
Growth Hormone Deficiency
Growth Hormone Receptor Deficiency
Central Nervous System
Recombinant Human Insulin Growth Factor 1
Insulin Growth Factor Binding Proteins
Human Mammary Epithelial Cells
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